SAB Biotherapeutics’ (SABS) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reissued their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research note published on Tuesday morning, Benzinga reports. Chardan Capital currently has a $25.00 price objective on the stock.

Separately, HC Wainwright lowered their price target on SAB Biotherapeutics from $10.00 to $6.00 and set a buy rating for the company in a research report on Tuesday, April 2nd.

SAB Biotherapeutics Stock Performance

Shares of SAB Biotherapeutics stock opened at $4.72 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.45 and a quick ratio of 5.45. The business has a fifty day simple moving average of $4.96 and a two-hundred day simple moving average of $3.11. SAB Biotherapeutics has a 12 month low of $4.00 and a 12 month high of $14.50.

Hedge Funds Weigh In On SAB Biotherapeutics

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of SAB Biotherapeutics by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 976,938 shares of the company’s stock worth $615,000 after purchasing an additional 14,200 shares during the last quarter. State Street Corp raised its position in SAB Biotherapeutics by 244.2% in the 1st quarter. State Street Corp now owns 42,341 shares of the company’s stock worth $159,000 after buying an additional 30,041 shares during the last quarter. Citadel Advisors LLC purchased a new position in SAB Biotherapeutics in the 3rd quarter worth about $28,000. Renaissance Technologies LLC purchased a new position in SAB Biotherapeutics in the 2nd quarter worth about $45,000. Finally, Millennium Management LLC purchased a new position in SAB Biotherapeutics in the 2nd quarter worth about $93,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.